Posted by Michael Wonder on 05 Oct 2023
Vedanta Biosciences announces first patient dosed in Phase 2 clinical trial of VE202 for the treatment of ulcerative colitis and receives fast track designation
4 October 2023 - VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis.
Vedanta also announced that the US FDA granted fast track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis.
